Most Current Smokers Desire Genetic Susceptibility Testing and Genetically-Efficacious Medication
The clinical translation of genetic research on nicotine dependence and treatment response requires acceptance of genetic testing by smokers. This study determines (1) which current smokers are receptive to genetic susceptibility testing for nicotine dependence and (2) to what potential extent smokers motivated to quit desire to take smoking cessation medication when hypothetical genetic results predict their pharmacogenetic medication response. Current smokers from a genetic nicotine dependence study (n = 1306) and an ongoing smoking cessation trial (n = 209) were surveyed on their hypothetical interest in seeing genetic testing results related to risk of nicotine dependence. Most current smokers (84.8%) reported high interest in receiving genetic testing results. Factors associated with high interest included age ≥ 40 years, having a college degree, and a positive medical history (≥1 medical condition). In the ongoing smoking cessation trial, current smokers motivated to quit (n = 474) were surveyed on their desire to take smoking cessation medication given hypothetical below or above average pharmacogenetic responses to the medication. When the hypothetical medication response changed from below to above average, significantly more smokers reported a desire to take medication (from 61.0% to 97.5%, p < .0001). These preliminary findings suggest that genetic testing for personalized smoking cessation treatment is well-received by smokers and that a positive hypothetical pharmacogenetic response increases desire to take smoking cessation medication among current smokers motivated to quit.
KeywordsInterest in genetic testing Smoking cessation Genetic predisposition testing Pharmacogenomic testing Precision medicine
Data reported in this publication were supported by the National Cancer Institute under Award Number P01CA089392 and by the National Institute on Drug Abuse under Award Number R01DA038076 (LSC). Dr. Hartz is supported by National Institutes of Health (NIH) grants R21AA024888, R21DA044744, and UL1TR002345. Dr. Ramsey is supported by NIH grant K12DA041449 and a grant from the Foundation for Barnes-Jewish Hospital. Dr. Bierut is supported by NIH grants R01DA036583, UL1TR002345, and P30CA091842. This content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
Compliance with Ethical Standards
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
Conflict of Interest
LJB is listed as an inventor on Issued U.S. Patent 8,080,371 “Markers for Addiction” covering the use of certain SNPs in determining the diagnosis, prognosis, and treatment of addiction, and served as a consultant for the pharmaceutical company Pfizer in 2008. The remaining authors declare no conflict of interest.
- Heatherton TF, Kozlowski LT, Frecker RC, Fagerstrom KO (1991) The Fagerstrom test for nicotine dependence: a revision of the Fagerstrom Tolerance Questionnaire. Br J Addict 86:1119–1127. https://doi.org/10.1111/j.1360-0443.1991.tb01879.x CrossRefPubMedGoogle Scholar
- U.S. Department of Health and Human Services (2014) The health consequences of smoking—50 years of progress. A report of the Surgeon General, AtlantaGoogle Scholar
- Wells QS, Freiberg MS, Greevy RA et al (2017) Nicotine metabolism-informed care for smoking cessation: a pilot precision RCT. Nicotine Tob Res:1–8. https://doi.org/10.1093/ntr/ntx235
- West R, Raw M, McNeill A et al (2015) Health-care interventions to promote and assist tobacco cessation: A review of efficacy, effectiveness and affordability for use in national guideline development. Addiction 110:1388–1403. https://doi.org/10.1111/add.12998 CrossRefPubMedPubMedCentralGoogle Scholar
- World Health Organization (2012) WHO Global Report: Mortality attributable of tobacco. World Health Organization, GenevaGoogle Scholar